Abstract
Bone metastases in urology are serious and common problem. Prostate cancer is the most common malignancy of men.
Renal and bladder cancer are also common urological malignancies with bone affection. Metastatic or osteoporotic affection of bone induced by cancer treatment is associated with the significant risk of adverse skeletal complications.
Prevention and treatment of skeletal related events (SREs) by zoledronic acid can improve quality of life, effectively prevent and postpone of SREs. Zoledronic acid is consider as a safe, well tolerated and effective in prevention and treatment of SREs by cancer of urological origin.
Intravenous application of zoledronic acid is a new gold standard in the prevention and in the treatment of skeletal related events in urooncology. As well our experience support these findings concerning safety and good tolerability by patients with serious bone affection of common urological malignancies.